Houston-based University of Texas MD Anderson Cancer Center has partnered with CureVac, a global biopharmaceutical company, to develop novel mRNA-based cancer vaccines.The partnership will develop differentiated cancer vaccine candidates for certain hematological and solid tumors with high unmet medical needs, according to an April 16 company news release.

位于休斯顿的德克萨斯大学MD安德森癌症中心与全球生物制药公司CureVac合作，开发新型基于mRNA的癌症疫苗。根据4月16日的公司新闻稿，该合作伙伴关系将为某些血液学和实体瘤开发分化型癌症候选疫苗，这些肿瘤的医疗需求尚未得到满足。

Both parties will contribute to identifying differentiated cancer antigens based on whole genome sequencing. The most promising vaccine candidates will go through initial phase 1 and 2 studies led by MD Anderson..

双方将有助于基于全基因组测序鉴定分化的癌症抗原。最有希望的候选疫苗将经历由MD Anderson领导的第一阶段和第二阶段的初步研究。。